Atoltivimab/maftivimab/odesivimab

Monoclonal antibody treatment for Ebola virus disease

Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a combination of three monoclonal antibodies used for the treatment of Ebola virus disease. This combination therapy is designed to target the Zaire ebolavirus, one of the most lethal strains of the Ebolavirus genus.

Mechanism of Action

Atoltivimab, maftivimab, and odesivimab are monoclonal antibodies that bind to the glycoprotein of the Ebola virus. This binding neutralizes the virus, preventing it from entering and infecting human cells. By targeting the glycoprotein, these antibodies block the virus's ability to replicate and spread within the host.

Development and Approval

The development of atoltivimab/maftivimab/odesivimab was a collaborative effort to address the urgent need for effective treatments during Ebola outbreaks. The combination was granted approval by the United States Food and Drug Administration (FDA) in October 2020, marking a significant milestone in the fight against Ebola.

Clinical Use

Ebola virus under electron microscope

Atoltivimab/maftivimab/odesivimab is administered as an intravenous infusion. It is indicated for the treatment of Ebola virus disease caused by the Zaire ebolavirus in adults and children, including newborns of mothers who have tested positive for the virus. The treatment is most effective when administered early in the course of the disease.

Safety and Efficacy

Clinical trials have demonstrated that atoltivimab/maftivimab/odesivimab significantly reduces mortality in patients with Ebola virus disease. The most common side effects include fever, chills, tachycardia, and hypotension, which are generally manageable with supportive care.

Related Pages

• Ebola virus disease
• Monoclonal antibody
• Zaire ebolavirus
• Ebolavirus